Vasovist® in Brain Tumor Imaging

Vasovist® (Gadofosveset, Bayer Schering Pharma AG, Berlin, Germany) represents a third generation of contrast agents. It is the first approved MR contrast medium with a pronounced and reversible protein binding, resulting in a long blood half-life. The agent is categorized as an intravascular or blood pool agent and was developed for MR angiographic applications, allowing imaging in a submillimeter resolution range in the equilibrium phase.